Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 6631-6639

  Condomines, Maud ^a,b,c   Quittet, Philippe ^a   Lu, Zhao Yang ^a   Nadal, Laure ^a   Latry, Pascal ^a   Lopez, Ernesto ^a   Baudard, Marion ^a   Requirand, Guilhem ^a   Duperray, Christophe ^a,c   Schved, Jean François ^a,b   Rossi, Jean François ^a,b   Tarte, Karin ^c   Klein, Bernard ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION;

EID: 33646869754     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.11.6631     Document Type: Article

References (56)

1. Philip, T., C. Guglielmi, A. Hagenbeek, R. Somers, H. Van der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J. Y. Cahn, J. L. Harousseau, et al. 1995. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 333: 1540-1545.
2. Attal, M., J. L. Harousseau, A. M. Stoppa, J. J. Sotto, J. G. Fuzibet, J. F. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, et al. 1996. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N. Engl. J. Med. 335: 91-97.
3. Gianni, A. M., S. Siena, M. Bregni, C. Tarella, A. C. Stem, A. Pileri, and G. Bonadonna. 1989. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2: 580-585.
4. Desikan, K. R., B. Barlogie, S. Jagannath, D. H. Vesole, D. Siegel, A. Passas, N. Munshi, S. Singhal, J. Mehta, S. Tindle, et al. 1998. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J. Clin. Oncol. 16: 1547-1553.
5. To, L. B., K. M. Shepperd, D. N. Haylock, P. G. Dyson, P. Charles, D. L. Thorp, B. M. Dale, G. W. Dart, M. M. Roberts, R. E. Sage, et al. 1990. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp. Hematol. 18: 442-447.
6. Winter, J. N., H. M. Lazarus, A. Rademaker, M. Villa, C. Mangan, M. Tallman, L. Jahnke, L. Gordon, S. Newman, K. Byrd, et al. 1996. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J. Clin. Oncol. 14: 277-286.
7. Narayanasami, U., R. Kanteti, J. Morelli, A. Klekar, A. Al-Olama, C. Keating, C. O'Connor, E. Berkman, J. K. Erban, K. A. Sprague, et al. 2001. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98: 2059-2064.
8. Koc, O. N., S. L. Gerson, B. W. Cooper, M. Laughlin, H. Meyerson, L. Kutteh, R. M. Fox, E. M. Szekely, N. Tainer, and H. M. Lazarus. 2000. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J. Clin. Oncol. 18: 1824-1830.
9. Levesque, J. P., Y. Takamatsu, S. K. Nilsson, D. N. Haylock, and P. J. Simmons. 2001. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98: 1289-1297.
10. Levesque, J. P., J. Hendy, Y. Takamatsu, B. Williams, I. G. Winkler, and P. J. Simmons. 2002. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp. Hematol. 30: 440-449.
11. Theilgaard-Monch, K., K. Raaschou-Jensen, H. Palm, K. Schjodt, C. Heilmann, L. Vindelov, N. Jacobsen, and E. Dickmeiss. 2001. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant. 28: 1073-1082.
12. Tayebi, H., F. Kuttler, P. Saas, A. Lienard, B. Petracca, V. Lapierre, C. Ferrand, T. Fest, J. Cahn, D. Blaise, et al. 2001. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp. Hematol. 29: 458-470.
13. Rutella, S., L. Pierelli, G. Bonanno, S. Sica, F. Ameglio, E. Capoluongo, A. Mariotti, G. Scambia, G. d'Onofrio, and G. Leone. 2002. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 100: 2562-2571.
14. Singh, R. K., M. L. Varney, K. Ino, J. M. Vose, P. J. Bierman, and J. E. Talmadge. 2000. Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients. Exp. Hematol. 28: 499-507.
15. Sloand, E. M., S. Kim, J. P. Maciejewski, F. Van Rhee, A. Chaudhuri, J. Barrett, and N. S. Young. 2000. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95: 2269-2274.
16. hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
17. Awwad, M., and R. J. North. 1988. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65: 87-92.
18. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
19. Turk, M. J., J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
20. O'Garra, A., and P. Vieira. 2004. Regulatory T cells and mechanisms of immune system control. Nat. Med. 10: 801-805.
21. + regulatory T cells. Trends Immunol. 25: 374-380.
22. + regulatory T cells. Int. Immunol. 16: 1643-1656.
23. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
24. + regulatory T cells are dependent on CTLA-4 expression. Eur. J. Immunol. 34: 3485-3496.
25. Porrata, L. F., M. A. Gertz, S. M. Geyer, M. R. Litzow, D. A. Gastineau, S. B. Moore, A. A. Pineda, K. L. Bundy, D. J. Padley, D. Persky, et al. 2004. The dose of infused lymphocytes in the autograft, directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 18: 1085-1092.
26. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
27. Lanzavecchia, A., and F. Sallusto. 2000. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 290: 92-97.
28. + effector and memory T cell generation. Nat. Immunol. 4: 835-842.
29. Tarte, K., G. Fiol, J. F. Rossi, and B. Klein. 2000. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia 14: 2182-2192.
30. Jourdan, M., X. G. Zhang, M. Portier, J. M. Boiron, R. Bataille, and B. Klein. 1991. IFN-α induces autocrine production of IL-6 in myeloma cell lines. J. Immunol. 147: 4402-4407.
31. + T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J. Acquir. Immune Defic. Syndr. 34: 475-481.
32. + T subsets with distinct replicative history and partial effector functions. Blood 102: 1779-1787.
33. high regulatory cells in human peripheral blood. J. Immunol. 167: 1245-1253.
34. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868.
35. Mackall, C. L., and R. E. Gress. 1997. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 157: 61-72.
36. Joshi, S. S., J. C. Lynch, S. Z. Pavletic, S. R. Tarantolo, S. J. Pirruccello, A. Kessinger, and M. R. Bishop. 2001. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 98: 1963-1970.
37. Proietti, E., G. Greco, B. Garrone, S. Baccarini, C. Mauri, M. Venditti, D. Carlei, and F. Belardelli. 1998. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101: 429-441.
38. + T cells. J. Immunol. 173: 5008-5020.
39. + T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
40. + lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors. Stem Cells Dev. 14: 310-316.
41. Hadaya, K., H. Kared, A. Masson, L. Chatenoud, and F. Zavala. 2005. G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse. J. Autoimmun. 24: 125-134.
42. + regulatory T-cells. Diabetes 54: 78-84.
43. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
44. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118.
45. + helper T cell responses in cancer patients. Blood 106: 1008-1011.
46. Guillaume, T., D. B. Rubinstein, and M. Symann. 1998. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92: 1471-1490.
47. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201: 723-735.
48. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28: 120-128.
49. Alpdogan, O., and M. R. van den Brink. 2005. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. 26: 56-64.
50. + regulatory T cells in inflamed synovia. J. Exp. Med. 201: 1793-1803.
51. Trickett, A., and Y. L. Kwan. 2003. T cell stimulation and expansion using anti-CD3/CD28 beads. J. Immunol. Methods. 275: 251-255.
52. + regulatory T cells from patient leukapheresis samples. J. Immunother. 28: 403-411.
53. Shpall, E. J. 1999. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant. 23(Suppl. 2): S13-S19.
54. Facon, T., J. L. Harousseau, F. Maloisel, M. Attal, J. Odriozola, A. Alegre, W. Schroyens, C. Hulin, R. Schots, P. Marin, et al. 1999. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 94: 1218-1225.
55. Pierelli, L., A. Perillo, S. Greggi, G. Salerno, P. B. Panici, G. Menichella, A. Fattorossi, G. Leone, S. Mancuso, and G. Scambia. 1999. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J. Clin. Oncol. 17: 1288.
56. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22: 1095-1102.